{"id":51727,"date":"2025-12-21T20:31:07","date_gmt":"2025-12-21T12:31:07","guid":{"rendered":"https:\/\/flcube.com\/?p=51727"},"modified":"2026-04-28T12:37:47","modified_gmt":"2026-04-28T04:37:47","slug":"beone-medicines-wins-fda-fast-track-for-gpc3-bispecific-in-liver-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51727","title":{"rendered":"BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>BeOne Medicines Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ONC:NASDAQ\">NASDAQ: ONC<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/6160:HKG\">HKG:\u202f6160<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688235:SHA\">SHA: 688235<\/a>) announced that the U.S. <strong>Food and Drug Administration (FDA)<\/strong> granted <strong>Fast Track Designation<\/strong> to <strong>BGB\u2011B2033<\/strong>, its <strong>GPC3x4\u20111BB bispecific antibody<\/strong>, for adult patients with <strong>hepatocellular carcinoma (HCC)<\/strong> who progressed on or after prior systemic treatment. BeOne is conducting a global, multi\u2011center <strong>Phase\u202f1 trial (NCT06427941)<\/strong> evaluating BGB\u2011B2033 alone and in combination with <strong>PD\u20111 inhibitor TEVIMBRA (tislelizumab)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Designation Date<\/strong><\/td><td>19\u202fDec\u202f2025<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>U.S. FDA<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>BGB\u2011B2033 (GPC3x4\u20111BB bispecific antibody)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Fast Track Designation (FTD)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>HCC with disease progression on or after prior systemic therapy<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td><strong>First GPC3x4\u20111BB bispecific<\/strong> to receive FTD for HCC<\/td><\/tr><tr><td><strong>Clinical Study<\/strong><\/td><td>NCT06427941 (Phase\u202f1), monotherapy and combination with TEVIMBRA<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-amp-mechanism\">Clinical Development &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study Design<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase<\/strong><\/td><td>Phase\u202f1<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>HCC patients post\u2011systemic therapy<\/td><\/tr><tr><td><strong>Treatment Arms<\/strong><\/td><td>BGB\u2011B2033 monotherapy; BGB\u2011B2033 + TEVIMBRA<\/td><\/tr><tr><td><strong>Primary Objectives<\/strong><\/td><td>Safety and anti\u2011tumor activity<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Bispecific targeting of GPC3 (tumor antigen) and 4\u20111BB (T\u2011cell costimulatory receptor)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><th>Context<\/th><\/tr><\/thead><tbody><tr><td><strong>Global HCC Market<\/strong><\/td><td><strong>$1.5\u20112.0\u202fbillion<\/strong> (2025)<\/td><td>High unmet need in third\u2011line+ setting<\/td><\/tr><tr><td><strong>GPC3 Expression<\/strong><\/td><td>70\u201180% of HCC tumors express GPC3<\/td><td>Ideal tumor\u2011associated target<\/td><\/tr><tr><td><strong>Bispecific Advantage<\/strong><\/td><td>Dual GPC3\/4\u20111BB targeting<\/td><td>Novel immuno\u2011oncology mechanism<\/td><\/tr><tr><td><strong>Peak Sales Potential<\/strong><\/td><td><strong>$300\u2011500\u202fmillion<\/strong><\/td><td>15\u201120% share of 3L+ HCC market<\/td><\/tr><tr><td><strong>Competition<\/strong><\/td><td>TKIs and PD\u20111 combos dominate<\/td><td>BGB\u2011B2033 offers differentiated approach<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding BGB\u2011B2033\u2019s clinical development, market potential, and competitive positioning. Actual results may differ due to regulatory feedback, clinical risks, or competitive responses.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced that the U.S. Food and Drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":51729,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[2092,847,28,3046,80,848],"class_list":["post-51727","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-beone-medicines","tag-hkg-6160","tag-multi-specific-antibodies","tag-nasdaq-onc","tag-priority-reviews","tag-sha-688235"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to BGB\u2011B2033, its GPC3x4\u20111BB bispecific antibody, for adult patients with hepatocellular carcinoma (HCC) who progressed on or after prior systemic treatment. BeOne is conducting a global, multi\u2011center Phase\u202f1 trial (NCT06427941) evaluating BGB\u2011B2033 alone and in combination with PD\u20111 inhibitor TEVIMBRA (tislelizumab).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=51727\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer\" \/>\n<meta property=\"og:description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to BGB\u2011B2033, its GPC3x4\u20111BB bispecific antibody, for adult patients with hepatocellular carcinoma (HCC) who progressed on or after prior systemic treatment. BeOne is conducting a global, multi\u2011center Phase\u202f1 trial (NCT06427941) evaluating BGB\u2011B2033 alone and in combination with PD\u20111 inhibitor TEVIMBRA (tislelizumab).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=51727\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-21T12:31:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-28T04:37:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1908.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51727#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51727\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer\",\"datePublished\":\"2025-12-21T12:31:07+00:00\",\"dateModified\":\"2026-04-28T04:37:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51727\"},\"wordCount\":271,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51727#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1908.webp\",\"keywords\":[\"BeOne Medicines\",\"HKG: 6160\",\"Multi-specific antibodies\",\"NASDAQ: ONC\",\"Priority reviews\",\"SHA: 688235\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51727#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51727\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=51727\",\"name\":\"BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51727#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51727#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1908.webp\",\"datePublished\":\"2025-12-21T12:31:07+00:00\",\"dateModified\":\"2026-04-28T04:37:47+00:00\",\"description\":\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to BGB\u2011B2033, its GPC3x4\u20111BB bispecific antibody, for adult patients with hepatocellular carcinoma (HCC) who progressed on or after prior systemic treatment. BeOne is conducting a global, multi\u2011center Phase\u202f1 trial (NCT06427941) evaluating BGB\u2011B2033 alone and in combination with PD\u20111 inhibitor TEVIMBRA (tislelizumab).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51727#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51727\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51727#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1908.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1908.webp\",\"width\":1080,\"height\":608,\"caption\":\"BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51727#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to BGB\u2011B2033, its GPC3x4\u20111BB bispecific antibody, for adult patients with hepatocellular carcinoma (HCC) who progressed on or after prior systemic treatment. BeOne is conducting a global, multi\u2011center Phase\u202f1 trial (NCT06427941) evaluating BGB\u2011B2033 alone and in combination with PD\u20111 inhibitor TEVIMBRA (tislelizumab).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=51727","og_locale":"en_US","og_type":"article","og_title":"BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer","og_description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to BGB\u2011B2033, its GPC3x4\u20111BB bispecific antibody, for adult patients with hepatocellular carcinoma (HCC) who progressed on or after prior systemic treatment. BeOne is conducting a global, multi\u2011center Phase\u202f1 trial (NCT06427941) evaluating BGB\u2011B2033 alone and in combination with PD\u20111 inhibitor TEVIMBRA (tislelizumab).","og_url":"https:\/\/flcube.com\/?p=51727","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-21T12:31:07+00:00","article_modified_time":"2026-04-28T04:37:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1908.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=51727#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=51727"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer","datePublished":"2025-12-21T12:31:07+00:00","dateModified":"2026-04-28T04:37:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=51727"},"wordCount":271,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=51727#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1908.webp","keywords":["BeOne Medicines","HKG: 6160","Multi-specific antibodies","NASDAQ: ONC","Priority reviews","SHA: 688235"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=51727#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=51727","url":"https:\/\/flcube.com\/?p=51727","name":"BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=51727#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=51727#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1908.webp","datePublished":"2025-12-21T12:31:07+00:00","dateModified":"2026-04-28T04:37:47+00:00","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to BGB\u2011B2033, its GPC3x4\u20111BB bispecific antibody, for adult patients with hepatocellular carcinoma (HCC) who progressed on or after prior systemic treatment. BeOne is conducting a global, multi\u2011center Phase\u202f1 trial (NCT06427941) evaluating BGB\u2011B2033 alone and in combination with PD\u20111 inhibitor TEVIMBRA (tislelizumab).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=51727#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=51727"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=51727#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1908.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1908.webp","width":1080,"height":608,"caption":"BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=51727#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1908.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51727"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51727\/revisions"}],"predecessor-version":[{"id":51730,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51727\/revisions\/51730"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/51729"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}